-
-
7 . Periodical
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
- 저자
- by Qin, Shukui; Chen, Minshan; Cheng, Ann-Lii; Kaseb, Ahmed O; Kudo, Masatoshi, et al.
- 소스
- The Lancet; November 2023, Vol. 402 Issue: 10415 p1835-1847, 13p